Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma
Date
August 18, 2016
Author(s)
Mauger, David T.
Paul, Ian M.
Moy, James N.
Boehmer, Susan J.
Szefler, Stanley J.
Fitzpatrick, Anne M.
Jackson, Daniel J.
Bacharier, Leonard B.
Cabana, Michael D.
Covar, Ronina
Holguin, Fernando
Lemanske, Robert F.
Martinez, Fernando D.
Pongracic, Jacqueline A.
Beigelman, Avraham
Benson, Mindy
Blake, Kathryn
Chmiel, James F.
Daines, Cori L.
Daines, Michael O.
Gentile, Deborah A.
Gower, W. Adam
Kumar, Harsha V.
Lang, Jason E.
Lazarus, Stephen C.
Lima, John J.
Ly, Ngoc
Marbin, Jyothi
Morgan, Wayne J.
Myers, Ross E.
Olin, J. Tod
Peters, Stephen P.
Raissy, Hengameh H.
Robison, Rachel G.
Ross, Kristie
Sorkness, Christine A.
Thyne, Shannon M.
Wechsler, Michael E.
Publisher
Massachusetts Medical Society
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sheehan, William, David T. Mauger, Ian M. Paul, James N. Moy, Susan J. Boehmer, Stanley J. Szefler, Anne M. Fitzpatrick et al. "Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma." New England Journal of Medicine 375, no. 7 (2016): 619-630. DOI: 10.1056/nejmoa1515990
Abstract
BACKGROUND
Studies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately designed trials evaluating this association in children are lacking.
METHODS
In a multicenter, prospective, randomized, double-blind, parallel-group trial, we enrolled 300 children (age range, 12 to 59 months) with mild persistent asthma and assigned them to receive either acetaminophen or ibuprofen when needed for the alleviation of fever or pain over the course of 48 weeks. The primary outcome was the number of asthma exacerbations that led to treatment with systemic glucocorticoids. Children in both treatment groups received standardized asthma-controller therapies that were used in a simultaneous, factorially linked trial.
RESULTS
Participants received a median of 5.5 doses (interquartile range, 1.0 to 15.0) of trial medication; there was no significant between-group difference in the median number of doses received (P = 0.47). The number of asthma exacerbations did not differ significantly between the two groups, with a mean of 0.81 per participant with acetaminophen and 0.87 per participant with ibuprofen over 46 weeks of follow-up (relative rate of asthma exacerbations in the acetaminophen group vs. the ibuprofen group, 0.94; 95% confidence interval, 0.69 to 1.28; P = 0.67). In the acetaminophen group, 49% of participants had at least one asthma exacerbation and 21% had at least two, as compared with 47% and 24%, respectively, in the ibuprofen group. Similarly, no significant differences were detected between acetaminophen and ibuprofen with respect to the percentage of asthma-control days (85.8% and 86.8%, respectively; P = 0.50), use of an albuterol rescue inhaler (2.8 and 3.0 inhalations per week, respectively; P = 0.69), unscheduled health care utilization for asthma (0.75 and 0.76 episodes per participant, respectively; P = 0.94), or adverse events.
CONCLUSIONS
Among young children with mild persistent asthma, as-needed use of acetaminophen was not shown to be associated with a higher incidence of asthma exacerbations or worse asthma control than was as-needed use of ibuprofen.
Other Available Sources
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
Subjects
Collection